H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Monopar Therapeutics Inc today and set a price target of $70.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andres Y. Maldonado has given his Buy rating due to a combination of factors surrounding Monopar Therapeutics Inc’s promising data on ALXN1840. The recent presentation at the American Neurological Association Annual Meeting highlighted significant improvements in neurological function for patients with Wilson disease, particularly those who were treatment-naïve and had severe conditions. This data, derived from multiple Phase 2 and Phase 3 trials, underscores ALXN1840’s potential as a transformative therapy, offering a substantial therapeutic advance not seen in over three decades.
Furthermore, the drug’s ability to mobilize copper effectively without causing paradoxical neurological worsening, coupled with its convenient once-daily dosing, positions it as a strong contender to replace current burdensome treatments like trientine and zinc. The unmet need for a safer, more effective treatment option is evident, with patient and caregiver testimonials supporting ALXN1840’s clinical benefits. The anticipation of an FDA meeting and subsequent NDA filing further bolsters the confidence in ALXN1840’s potential market impact, justifying the Buy rating.
In another report released on September 9, BTIG also initiated coverage with a Buy rating on the stock with a $87.00 price target.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MNPR in relation to earlier this year.